Literature DB >> 17171496

Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer.

Ryuichiro Doi1, Kazuhiro Kami, Daisuke Ito, Koji Fujimoto, Yoshiya Kawaguchi, Michihiko Wada, Masafumi Kogire, Ryo Hosotani, Masayuki Imamura, Shinji Uemoto.   

Abstract

BACKGROUND: The survival curve of patients who undergo surgical resection of pancreatic cancer displays a steep decline within 1 year and a relatively slow decline thereafter. The patients with a short survival time may have identifiable clinicopathologic factors that lead to rapid relapse. STUDY
DESIGN: We analyzed clinicopathologic factors in 133 patients who underwent margin-negative pancreatoduodenectomy with extended radical lymphadenectomy for invasive ductal carcinoma of the pancreas to detect factors that could be responsible for the short survival.
RESULTS: Tumor size, invasion of the anterior pancreatic capsule, retroperitoneal invasion, portal venous invasion, major arterial invasion, and metastasis to the para-aortic lymph nodes were variables associated with survival time in univariate analysis. Metastasis to the para-aortic lymph nodes was the single independent factor with a significant association with mortality in multivariate analysis. Some 84% of the patients who had positive para-aortic lymph nodes died within 1 year, versus 46% of the patients with negative nodes.
CONCLUSIONS: Although tumors that involve the para-aortic lymph nodes may technically be resectable, the expected postoperative survival time for most patients is less than 1 year. If para-aortic nodal metastasis is detected, alternative treatment strategies should be considered.

Entities:  

Mesh:

Year:  2007        PMID: 17171496     DOI: 10.1007/s00268-005-0730-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  40 in total

1.  Chemoradiotherapy in patients with pancreatic carcinoma: phase-I study with a fixed radiation dose and escalating doses of weekly gemcitabine.

Authors:  Natsuo Oya; Keiko Shibuya; Takashi Sakamoto; Takashi Mizowaki; Ryuichiro Doi; Koji Fujimoto; Masayuki Imamura; Yasushi Nagata; Masahiro Hiraoka
Journal:  Pancreatology       Date:  2005-12-01       Impact factor: 3.996

2.  External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications.

Authors:  Y Nishimura; R Hosotani; Y Shibamoto; M Kokubo; S Kanamori; K Sasai; M Hiraoka; G Ohshio; M Imamura; M Takahashi; M Abe
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-08-01       Impact factor: 7.038

3.  Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas.

Authors:  K W Millikan; D J Deziel; J C Silverstein; T M Kanjo; J D Christein; A Doolas; R A Prinz
Journal:  Am Surg       Date:  1999-07       Impact factor: 0.688

Review 4.  Japan Pancreatic Cancer Registry: current status.

Authors:  M Yamamoto; O Ohashi; Y Saitoh
Journal:  Pancreas       Date:  1998-04       Impact factor: 3.327

5.  Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer.

Authors:  S M de Lange; C J van Groeningen; O W M Meijer; M A Cuesta; J A Langendijk; J M G H van Riel; H M Pinedo; G J Peters; S Meijer; B J Slotman; G Giaccone
Journal:  Eur J Cancer       Date:  2002-06       Impact factor: 9.162

6.  Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival.

Authors:  Cristina R Ferrone; Michael W Kattan; James S Tomlinson; Sarah P Thayer; Murray F Brennan; Andrew L Warshaw
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

7.  Pancreatic Cancer Registry in Japan: 20 years of experience.

Authors:  Seiki Matsuno; Shinichi Egawa; Shoji Fukuyama; Fuyuhiko Motoi; Makoto Sunamura; Shuji Isaji; Toshihide Imaizumi; Shuichi Okada; Hiroyuki Kato; Kouichi Suda; Akimasa Nakao; Takehisa Hiraoka; Ryo Hosotani; Kazunori Takeda
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

8.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

9.  Pylorus-preserving pancreatoduodenectomy. Is it an adequate cancer operation.

Authors:  J I Tsao; R L Rossi; J A Lowell
Journal:  Arch Surg       Date:  1994-04

10.  Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.

Authors:  Charles J Yeo; John L Cameron; Keith D Lillemoe; Taylor A Sohn; Kurtis A Campbell; Patricia K Sauter; JoAnn Coleman; Ross A Abrams; Ralph H Hruban
Journal:  Ann Surg       Date:  2002-09       Impact factor: 12.969

View more
  27 in total

1.  Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Yoshio Yuasa; Taijiro Sueda
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

2.  Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer.

Authors:  Hisashi Imai; Ryuichiro Doi; Hiroyuki Kanazawa; Naoko Kamo; Masayuki Koizumi; Toshihiko Masui; Yasuhiro Iwanaga; Yoshiya Kawaguchi; Yasutsugu Takada; Hiroyoshi Isoda; Shinji Uemoto
Journal:  Int J Clin Oncol       Date:  2010-03-16       Impact factor: 3.402

Review 3.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

4.  Feasibility and reliability of pancreatic cancer staging using a new confocal non-fluorescent microscopy probe: a double-blind study in rats.

Authors:  Cherif Akladios; Vivian De Ruijter; Sylvana Perretta; Marc Aprahamian; Mihaela Ignat; Veronique Lindner; Gerlinde Averous; Bernard Dallemagne; Jacques Marescaux
Journal:  Surg Endosc       Date:  2016-06-28       Impact factor: 4.584

5.  Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy.

Authors:  Arsen Osipov; Jason Naziri; Andrew Hendifar; Deepti Dhall; Joanne K Rutgers; Shefali Chopra; Quanlin Li; Mourad Tighiouart; Alagappan Annamalai; Nicholas N Nissen; Richard Tuli
Journal:  J Gastrointest Oncol       Date:  2016-04

Review 6.  Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas.

Authors:  Daniel Åkerberg; Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

Review 7.  Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features.

Authors:  Christos Agalianos; Nikolaos Gouvas; Kleo Papaparaskeva; Christos Dervenis
Journal:  HPB (Oxford)       Date:  2016-06-03       Impact factor: 3.647

8.  Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle.

Authors:  Shaunagh McDermott; Sarah P Thayer; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; Ralph Weissleder; Mukesh G Harisinghani
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

Review 9.  Staging cancer of the pancreas.

Authors:  G Morana; L Cancian; R Pozzi Mucelli; C Cugini
Journal:  Cancer Imaging       Date:  2010-10-04       Impact factor: 3.909

Review 10.  Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis.

Authors:  Lennart B van Rijssen; Poorvi Narwade; Nadine C M van Huijgevoort; Dorine S J Tseng; Hjalmar C van Santvoort; Isaac Q Molenaar; Hanneke W M van Laarhoven; Casper H J van Eijck; Olivier R C Busch; Marc G H Besselink
Journal:  HPB (Oxford)       Date:  2016-05-27       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.